🟢 Milestone Pharmaceuticals is trading 5% up in pre-market, with no identified company catalyst

Milestone Pharmaceuticals is trading at $0.80, up 5.20%, in pre-market; no specific October 12 company catalyst was identified.

• The company announced on October 9 that the first European participant had enrolled in its Phase 3 ReVeRA-301 trial; available reporting does not establish the announcement as the cause of this move.
• Healthcare’s reported 1.58% pre-market gain offers supportive sector context, with managed-care strength cited as the sector driver, not a company-specific development.